| Abstrakt: |
Objectives: The aim of the present study was to present the market scenario of biotechnological drugs, especially insulin. In addition to Brazil, a study was conducted that considered the United States market, which has the largest market of biotechnological products in the world and in China, for presenting an increase in investments in the biotechnology area and is a BRICS member. Methods: A market survey of biotechnological drugs and insulin was carried out. The information that was used is provided through the IMS Health Customer Portal from 2010 to 2014, and was searched in the AliceWeb database between 2011 and 2016, and we consulted Insights magazine (published by IMS Health). Information was also obtained from the Brazilian Association of the Pharmaceutical and Pharmaceutical Industries (Abiquif) (2012–2016) and from the International Diabetes Federation (IDF), available on its websites, to identify sales of biotech drugs and, more specifically, insulin. Key findings: The deficit in the Brazilian trade balance between 2012 and 2016, related to medicines, remains high, mainly driven by the acquisition of high value‐added drugs, mainly biotechnological drugs, such as insulin. In 5 years (2010–2014), the value of the commercialization of insulin increased by an average of 100%. In 2010, the total marketing value of insulin was approximately US $16 billion, and in 2014, it was approximately US $29 billion. The three laboratories that stand out in the world, namely, Sanofi, Lilly and Novo Nordisk, are the main laboratories that market insulin in Brazil. Conclusions: The observed results make evident the import dependence for the acquisition of insulin, which can lead to a national shortage and possible cases of death and sequelae from diabetes in patients who did not receive adequate treatment, besides contributing to the trade deficit. [ABSTRACT FROM AUTHOR] |
Plný text